Cite
HARVARD Citation
Hochmair, M. et al. (n.d.). 489POverall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study. Annals of oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hochmair, M. et al. (n.d.). 489POverall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study. Annals of oncology. p. . [Online].